Sector: Life Sciences

Latest content

The 2021 trends that shaped the IP market in five major industries

In-house experts highlight the year’s most important patent developments in auto, life sciences, software, semiconductors and telecoms

20 December 2021

US legislators call for screws to be tightened on pharma patent strategies

New report issued by Democrats in the House of Representatives indicates a change of tack in approaching potential reforms may be on the cards

17 December 2021

CJEU to tackle SPC uncertainties over combination products

Finnish court makes new referral for the justices on the Luxembourg-based tribunal to consider

16 December 2021

Generics win battle in war against tough Californian patent settlement rules

A preliminary injunction has been issued against the state’s strict reverse payment law, but antitrust considerations are here to stay in IP litigation settlements

14 December 2021

PepsiCo suffers big loss following David-vs-Goliath battle with Indian farmers

India revokes company’s exclusive right to potato variety used in Lay’s chips, in case that illustrates limits of country’s agricultural IP protections

10 December 2021

Why some patent owners may pursue a wait-and-see strategy for the UPC

Three-quarters of IP market leaders in latest IAM Panel Report say they’re taking a cautious approach to the venue, which passed another key milestone for establishment last week

10 December 2021

Germany’s new government is the last hope for covid IP waiver advocates

A post-Merkel change of approach by the country’s recently agreed traffic light coalition government could change the momentum of TRIPS suspension talks – but don’t bet on it

07 December 2021

Validity rate for Chinese patents ticks upward, but patent owners in top tech areas face tough road

While more than half of invention patents survive invalidation unscathed, key life science and communications classes see higher knock-out rate

06 December 2021

Australia under-invests in IP, and recent government proposals will not fix that

Saturday Opinion: In-house leaders say a mooted patent box regime limited to life sciences will reward companies that get patents already, failing to encourage IP investment in new industries

04 December 2021

CAFC tees up patent fight over multi-billion-dollar Moderna covid revenues

Arbutus Biopharma’s shares soar in anticipation of mRNA jab royalty lawsuit after Federal Circuit ruling

03 December 2021

Get unlimited access to all IAM content